Section 781 Hemp & CBD: FDA Regulatory Framework & Enforcement

Overview

The hemp and CBD industry is barreling toward a cliff. On November 12, 2026, Section 781 of the Federal Food, Drug, and Cosmetic Act takes full effect, replacing the permissive 2018 Farm Bill framework with restrictions so severe that the U.S. Hemp Roundtable estimates 95% of existing hemp-derived cannabinoid products will become federally unlawful overnight. An estimated $30 billion industry, over 300,000 jobs, and $1.5 billion in state tax revenue hang in the balance.

Section 781 was enacted on November 12, 2025, as part of the Continuing Appropriations and Agriculture Act (P.L. 119-37, Division B). It represents the most significant change to federal hemp regulation since the 2018 Farm Bill first removed hemp from the Controlled Substances Act. The provision was designed to close what critics called the "THC loophole" -- a gap in the 2018 Farm Bill's definition that allowed intoxicating hemp products (delta-8 THC gummies, THCA flower, THC-infused beverages) to proliferate in gas stations and convenience stores across America while technically remaining legal under federal law.

But the fix may have overshot. The 0.4 milligram total THC per container cap does not just eliminate intoxicating products -- it threatens non-intoxicating CBD wellness products, full-spectrum hemp extracts, and even some topical formulations that contain trace amounts of THC well below any psychoactive threshold.

For companies in the hemp and CBD space, the next eight months are a countdown. Understanding what Section 781 requires, what remains unresolved, and what legislative efforts might alter the outcome is not optional -- it is essential to survival.

Current Regulatory Status

The Federal Framework as of March 2026

CBD and hemp-derived cannabinoid products exist under overlapping and often contradictory federal authorities:

Section 781 of the FD&C Act (enacted November 12, 2025; effective November 12, 2026): The centerpiece of the current regulatory landscape. Section 781 rewrites the statutory definition of hemp under 7 U.S.C. Section 1639o, replacing the 2018 Farm Bill's delta-9-only THC threshold with a total THC standard. Key provisions:

• Total THC definition: Hemp is now Cannabis sativa L. with a total THC concentration (including delta-9 THC, THCA, delta-8 THC, and all other THC isomers) of not more than 0.3% on a dry weight basis.
• Per-container cap: Final hemp-derived cannabinoid products intended for human or animal use through ingestion, inhalation, or topical application must contain no more than 0.4 mg of total THC per container.
• Container definition: The "innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product in which the final hemp-derived cannabinoid product is enclosed for retail sale to consumers, such as a jar, bottle, bag, box, can, carton, or cartridge."
• Intermediate products: Must contain no more than 0.3% total THC on a dry weight basis after decarboxylation.
• Synthetic ban: Products containing cannabinoids that are not capable of being naturally produced by Cannabis sativa L. are excluded from the definition of hemp. Products containing cannabinoids that could be naturally produced but were "synthesized or manufactured outside the plant" are also excluded.

FDA's January 2023 determination: CBD cannot legally be marketed as a dietary supplement or added to conventional food under existing frameworks. The drug preclusion clause (Section 201(ff)(3)(B) of the FD&C Act) bars CBD from the dietary supplement definition because Epidiolex (the FDA-approved CBD drug) was the subject of substantial clinical investigations before CBD was marketed in food or supplements. Section 301(ll) prohibits introducing food containing CBD into interstate commerce.

This means CBD faces a double prohibition: it cannot be sold as a food or supplement (per the drug preclusion clause), and any THC it contains is now subject to Section 781's restrictive caps.

FDA Guidance: Missed Deadlines

Section 781 required the FDA to publish four lists within 90 days of enactment (by approximately February 10, 2026):

1. All cannabinoids known to be naturally produced by Cannabis sativa L.
2. All THC-class cannabinoids naturally occurring in the plant
3. All cannabinoids with similar effects to, or marketed as having similar effects to, THC-class cannabinoids
4. Additional specificity on the definition of "container"

The FDA missed this deadline. As of March 2026, none of these lists have been published. This failure has compounded uncertainty across the industry, leaving companies unable to determine with precision which cannabinoids will be regulated, which products might qualify for exemptions, and how multi-unit packaging will be treated under the container definition.

The FDA has not publicly explained the delay or provided a revised timeline.

Congressional Responses

Two significant legislative proposals are attempting to modify or replace Section 781:

American Hemp Protection Act of 2025 (H.R. 6209): Introduced November 17, 2025, by Representative Nancy Mace (R-SC). The bill would strike Section 781 in its entirety, restoring the 2018 Farm Bill definition. This is the most aggressive rollback proposal -- it would return the industry to the pre-November 2025 status quo with no additional consumer protections.

Cannabinoid Safety and Regulation Act (CSRA): Introduced December 2025 by Senators Ron Wyden (D-OR) and Jeff Merkley (D-OR). This 84-page bill takes a different approach: rather than repealing Section 781, it would replace the prohibition with a comprehensive federal regulatory framework. Key provisions include:

• THC limits of 5 mg per serving and 50 mg per container for edibles
• Beverage limit of 10 mg per container
• Federal age gate of 21 years
• Mandatory testing standards for pesticides, heavy metals, chemical byproducts, and additives
• Packaging and labeling requirements
• Restrictions on child-appealing packaging

Neither bill has advanced to committee markup as of March 2026. The 2026 Farm Bill reauthorization, currently progressing through Congress, has been cited as another potential vehicle for addressing hemp regulation, but the intoxicating hemp ban provisions remain unchanged in the latest Farm Bill text.

Key Deadlines

Date	Event	Status
December 20, 2018	2018 Farm Bill enacted; hemp removed from Controlled Substances Act	Completed
June 25, 2018	FDA approves Epidiolex (CBD); triggers drug preclusion clause	Completed
January 26, 2023	FDA determines existing frameworks inadequate for CBD	Completed
November 12, 2025	Section 781 enacted as part of P.L. 119-37	Completed
February 10, 2026	FDA deadline for cannabinoid lists and container guidance	Missed
November 12, 2026	Section 781 restrictions take full effect	Upcoming

Detailed Analysis

The 2018 Farm Bill: How the Loophole Opened

The 2018 Agriculture Improvement Act defined hemp as Cannabis sativa L. with a delta-9 THC concentration of not more than 0.3% on a dry weight basis. This definition was narrowly focused on delta-9 THC -- the primary psychoactive compound in cannabis. The intent was to allow agricultural hemp production for fiber, grain, and CBD extraction while maintaining federal prohibition on marijuana.

What lawmakers did not anticipate was the chemistry. Delta-8 THC, a naturally occurring cannabinoid present in trace amounts in hemp, produces psychoactive effects similar to (though milder than) delta-9 THC. Manufacturers discovered they could convert abundant CBD into delta-8 THC through isomerization -- an acid-catalyzed chemical process. Because the resulting product contained less than 0.3% delta-9 THC, it technically met the Farm Bill's definition of hemp.

By 2023, delta-8 THC products had exploded into a multi-billion dollar market. Gas stations, convenience stores, and online retailers sold delta-8 gummies, vapes, and edibles with little to no age verification, testing requirements, or labeling standards. THCA flower -- raw cannabis that converts to delta-9 THC when heated -- entered the market through a similar loophole: because THCA is not delta-9 THC until decarboxylated, products could contain high levels of THCA while staying under the delta-9 threshold on lab tests.

The result was a largely unregulated intoxicating market operating under the cover of agricultural hemp law. Poison control centers reported a surge in calls related to delta-8 products, particularly involving children who consumed products in packaging designed to mimic popular candy and snack brands.

Section 781: Closing the Loophole

Section 781 closes the delta-8/THCA loophole by redefining hemp to use total THC concentration rather than delta-9 alone. This single change -- from delta-9 to total THC -- eliminates the chemical workaround that enabled the intoxicating hemp market.

But the provision goes further with the 0.4 mg per container cap. This limit is extraordinarily low. To put it in context:

• A typical CBD oil tincture (30 mL bottle) containing 1,000 mg of full-spectrum CBD extract would contain approximately 20-30 mg of total THC. Under Section 781, that product would need to contain less than 0.4 mg -- a reduction of roughly 98%.
• A single CBD gummy with 25 mg of broad-spectrum CBD might contain 0.5-1.0 mg of THC. That single gummy exceeds the entire container allowance.
• Hemp-derived THC beverages, which have become a significant market in states like Minnesota and Connecticut, typically contain 2.5-5 mg of THC per serving. One can exceeds the Section 781 limit by over 500%.

The practical effect is that virtually all CBD products containing any detectable THC -- including full-spectrum extracts marketed for wellness, not intoxication -- will be unlawful after November 12, 2026.

CBD isolate products (those containing purified CBD with no measurable THC) would not be affected by the THC cap. However, these products remain subject to the FDA's separate prohibition on CBD in food and supplements under the drug preclusion clause. In other words, even a zero-THC CBD product cannot legally be sold as a food or dietary supplement.

The Enforcement Landscape

FDA and FTC enforcement against hemp and CBD companies has intensified steadily since 2021, with several distinct patterns emerging from warning letter activity.

Disease claims remain the primary trigger. The FDA has consistently targeted companies making explicit therapeutic claims for CBD products -- marketing them as treatments for cancer, Alzheimer's disease, anxiety disorders, chronic pain, and COVID-19. These claims trigger the unapproved new drug provisions of the FD&C Act regardless of the product's CBD or THC content.

Child-appealing packaging draws joint FDA/FTC action. In July 2023, the FDA and FTC jointly issued cease-and-desist letters to six companies selling delta-8 THC products in packaging mimicking Froot Loops, Cap'n Crunch, Flamin' Hot Cheetos, Chips Ahoy, Skittles, and Sour Patch Kids. A second round of joint letters followed in July 2024, targeting five additional companies (Hippy Mood, Earthly Hemps, Shamrockshrooms.com, Mary Janes Bakery Co., and Life Leaf Medical CBD Center) along with a standalone FDA letter to GrowGod LLC.

Adulterated food enforcement is expanding. In December 2023, the FDA issued a significant warning letter to Hemp-XR.com, declaring delta-8 and CBD gummies to be "adulterated foods" -- a legal characterization that goes beyond the typical "unapproved new drug" framing. This signaled a potential shift toward using food safety authorities (rather than just drug authorities) to enforce against cannabinoid products.

Our database tracks 10 enforcement actions against hemp/CBD companies, including warning letters to Bearly Legal Hemp, Shake Hemp, Earthly Hemps, Hemp XR, PureChemPros, Exclusive Hemp Farms, NC Hemp Shoppe, Cloud Hempistry, Delta 8 Hemp, and Functional Remedies. Common violations span unapproved drug claims, food adulteration, and misbranding.

FTC's separate enforcement track. The FTC has pursued hemp companies for deceptive billing practices independent of product safety concerns. In July 2024, the FTC filed a complaint against Legion Media and related companies for fraudulently charging consumers who purchased CBD and keto-related products, resulting in $27.6 million in consumer refunds announced in December 2025.

The State Patchwork

Section 781 does not expressly preempt state law, but it creates significant conflict-of-law issues. States have responded to the federal changes in three broad categories:

Restrictive states (banning intoxicating hemp): Ohio enacted Senate Bill 56 in December 2025, categorically banning intoxicating hemp products. Several other states had already restricted or banned delta-8 THC before the federal changes, including New York, Colorado, Oregon, and Vermont.

Regulatory states (permitting with controls): Minnesota's model -- incorporating licensing, age verification (21+), labeling standards, and per-serving THC limits -- has been cited by federal legislators as evidence that state regulation can work. Connecticut and other states have implemented similar frameworks for THC beverages and edibles.

Permissive states (minimal restrictions): Some states, particularly in the Southeast, had allowed largely unregulated sale of hemp-derived THC products. These markets face the most disruption from Section 781.

The conflict preemption issue is significant: if a state law permits the sale of hemp-derived THC products above the new federal threshold, businesses cannot comply with both laws simultaneously. Federal law would effectively override state permissions for products exceeding 0.4 mg total THC per container, potentially nullifying state-licensed hemp THC markets for both interstate and intrastate commerce.

Senator Rand Paul (R-KY) has publicly considered legislation returning hemp regulatory authority to the states, which would formalize the existing patchwork rather than resolve it.

DEA and Controlled Substances Act Implications

Section 781's redefinition of hemp has direct consequences under the Controlled Substances Act (CSA). Products that no longer meet the statutory definition of hemp after November 12, 2026, revert to the definition of marijuana -- a Schedule I controlled substance. This means:

• Manufacturing, distributing, or possessing products containing more than 0.4 mg of total THC per container could constitute federal drug offenses.
• Existing inventory that was lawfully produced under the 2018 Farm Bill definition may become controlled substances if not sold or destroyed before the effective date.
• Banking and financial services, already cautious about the hemp industry, may further restrict access.

New Jersey has already advanced legislation requiring liquidation of non-compliant inventory on an accelerated timeline, with post-November 2026 channeling of THC beverages into the state's licensed cannabis regulatory framework.

A separate executive order signed in 2025 directs federal agencies to accelerate rescheduling of marijuana from Schedule I to Schedule III. If finalized, this could affect how products falling out of the hemp definition are treated, but rescheduling does not create a legal pathway for consumer hemp products.

Affected Product Categories

Section 781 and FDA's CBD enforcement actions affect products across multiple sectors:

Botanicals and herbal products: Hemp flower, botanical blends containing hemp-derived cannabinoids, and herbal wellness formulations. Products containing THCA flower or delta-8 THC face the total THC redefinition.

Vape and inhalable products: Hemp-derived THC and CBD vape cartridges, disposable vapes, and inhalable products. These are explicitly covered by Section 781's "inhalation" language and face both the THC cap and synthetic cannabinoid ban.

Topical products: CBD creams, lotions, balms, and transdermal patches. While often assumed to be lower-risk, Section 781 explicitly covers "topical use" and applies the 0.4 mg container cap. Full-spectrum topical products may exceed this threshold.

What Companies Should Do

The November 12, 2026, effective date creates an eight-month window for compliance planning. Companies manufacturing, distributing, or selling hemp-derived cannabinoid products should take the following steps:

1. Audit your product portfolio for THC content. Test every product SKU for total THC (not just delta-9). Identify which products exceed 0.4 mg total THC per container. This is the most urgent task -- you cannot plan without knowing your exposure.

2. Reformulate or discontinue non-compliant products. Products exceeding the 0.4 mg threshold have three options: reformulate to CBD isolate or broad-spectrum extract with total THC below the cap; transition to state-licensed cannabis programs where available; or discontinue. Lead times for reformulation, stability testing, and packaging changes mean this work needs to begin immediately.

3. Eliminate all disease claims from marketing materials. The FDA and FTC have demonstrated that health claims on CBD products are the most reliable enforcement trigger. Review all product labels, websites, social media, and marketing collateral. Remove any claims that CBD treats, cures, prevents, or mitigates any disease or condition. This applies regardless of Section 781 compliance.

4. Address child-appealing packaging. Any packaging that resembles established candy, snack, or cereal brands creates immediate enforcement risk. The FDA/FTC joint enforcement actions in 2023 and 2024 make clear that copycat packaging is a priority target.

5. Develop an inventory liquidation plan. Products lawfully manufactured under the 2018 Farm Bill definition become non-compliant on November 12, 2026. Plan to sell through or destroy non-compliant inventory before that date. Some states (e.g., New Jersey) are imposing accelerated liquidation timelines.

6. Monitor the legislative landscape. The American Hemp Protection Act (H.R. 6209) and the Cannabinoid Safety and Regulation Act (CSRA) could significantly alter the outcome. The 2026 Farm Bill reauthorization is another potential vehicle for change. Neither is guaranteed to pass, and compliance planning should assume Section 781 takes effect as written.

7. Watch for FDA's cannabinoid lists. When (and if) the FDA publishes its overdue cannabinoid classifications, they will determine which specific compounds are regulated and how the container definition applies. These lists could narrow or expand the scope of products affected.

8. Engage legal counsel on state-by-state compliance. The state patchwork means that a product legal in one state may be illegal in the next. Multi-state operators need jurisdiction-specific compliance strategies, particularly in states that are channeling hemp THC products into cannabis regulatory frameworks.

9. Evaluate banking and insurance exposure. Financial institutions and insurers are already reassessing hemp industry relationships in light of Section 781. Proactively communicate with your bank and insurer about your compliance strategy. Companies with products that will become controlled substances under the CSA face potential loss of banking access.

10. Subscribe to regulatory monitoring. The hemp-CBD regulatory landscape is changing faster than any other sector the FDA oversees. Monthly or weekly regulatory intelligence briefings are not a luxury -- they are a necessity for any company with products in this space. Policy Canary tracks FDA warning letters, enforcement actions, and regulatory changes across the hemp and CBD landscape in real time.